Metformin in Safety and Efficacy in Gouty Patients

ConditionGout

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-60

SponsorMostafa Bahaa

About this trial

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.

Disqualifiers

Systemic disorders such as cardiovascular, neurological, coronary artery disease.

Hypertension, hyperlipidemia, diabetes mellitus, active infections.

Other inflammatory or autoimmune diseases.

Patients on biologics,

Trial design

Design model

Parallel

Treatments tested in this trial

placebo
Other intervention
Placebo will have the same look of metformin
Metformin
Drug
Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Treatment groups

70 Participants

are divided into 2 treatment groups

Group A: Control groupActive comparator 1 intervention

Group B: Metformin groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

- Clinical assessment of disease activity

\- Clinical assessment of disease activity by assessing patient and physician VAS visual analog scale (0-10 cm);

Time frame

3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mostafa Bahaa

Lead sponsor

Tanta University

Sponsor institution

Source ClinicalTrials.gov

Apply now